MA31753B1 - Detection amelioree de l'expression de mage-a - Google Patents
Detection amelioree de l'expression de mage-aInfo
- Publication number
- MA31753B1 MA31753B1 MA32736A MA32736A MA31753B1 MA 31753 B1 MA31753 B1 MA 31753B1 MA 32736 A MA32736 A MA 32736A MA 32736 A MA32736 A MA 32736A MA 31753 B1 MA31753 B1 MA 31753B1
- Authority
- MA
- Morocco
- Prior art keywords
- mage
- gene
- primer
- expression
- methylation
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 abstract 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 2
- 230000011987 methylation Effects 0.000 abstract 2
- 238000007069 methylation reaction Methods 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000007855 methylation-specific PCR Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/30—Oligonucleotides characterised by their secondary structure
- C12Q2525/301—Hairpin oligonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2561/00—Nucleic acid detection characterised by assay method
- C12Q2561/113—Real time assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
- C12Q2565/10—Detection mode being characterised by the assay principle
- C12Q2565/101—Interaction between at least two labels
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96012807P | 2007-09-17 | 2007-09-17 | |
| PCT/GB2008/003142 WO2009037438A1 (en) | 2007-09-17 | 2008-09-17 | Improved detection of mage-a expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA31753B1 true MA31753B1 (fr) | 2010-10-01 |
Family
ID=40239643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA32736A MA31753B1 (fr) | 2007-09-17 | 2010-04-01 | Detection amelioree de l'expression de mage-a |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US8481700B2 (enExample) |
| EP (2) | EP2201131B8 (enExample) |
| JP (1) | JP5406839B2 (enExample) |
| KR (1) | KR20100085917A (enExample) |
| CN (1) | CN101932723B (enExample) |
| AU (1) | AU2008300397A1 (enExample) |
| BR (1) | BRPI0817008A2 (enExample) |
| CA (2) | CA2699853A1 (enExample) |
| CO (1) | CO6260156A2 (enExample) |
| CR (1) | CR11504A (enExample) |
| DO (1) | DOP2010000076A (enExample) |
| EA (1) | EA017879B1 (enExample) |
| IL (1) | IL204525A0 (enExample) |
| MA (1) | MA31753B1 (enExample) |
| MX (1) | MX2010002965A (enExample) |
| NZ (2) | NZ596545A (enExample) |
| WO (2) | WO2009037441A1 (enExample) |
| ZA (1) | ZA201001878B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130237445A1 (en) * | 2010-09-14 | 2013-09-12 | The University Of North Carolina At Chapel Hill | Methods and kits for detecting melanoma |
| WO2012129488A2 (en) * | 2011-03-23 | 2012-09-27 | Virginia Commonwealth University | Gene signatures associated with rejection or recurrence of cancer |
| CN102251033B (zh) * | 2011-07-05 | 2013-03-20 | 北京大学人民医院 | 基于mage-a3基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒 |
| US20140213471A1 (en) | 2013-01-24 | 2014-07-31 | California Institute Of Technology | Chromophore-based characterization and detection methods |
| CA2902916C (en) * | 2013-03-14 | 2018-08-28 | Mayo Foundation For Medical Education And Research | Detecting neoplasm |
| US10184154B2 (en) | 2014-09-26 | 2019-01-22 | Mayo Foundation For Medical Education And Research | Detecting cholangiocarcinoma |
| GB2550712B (en) * | 2015-02-26 | 2021-01-13 | Hitachi High Tech Corp | Method for constructing hairpin-containing nucleic acid molecules for nanopore sequencing |
| CN107532124B (zh) | 2015-03-27 | 2022-08-09 | 精密科学公司 | 检测食管疾病 |
| CN105100961B (zh) * | 2015-07-23 | 2018-03-13 | 华为技术有限公司 | 视频缩略图生成方法及生成装置 |
| US11685955B2 (en) | 2016-05-16 | 2023-06-27 | Dimo Dietrich | Method for predicting response of patients with malignant diseases to immunotherapy |
| DE102016005947B3 (de) * | 2016-05-16 | 2017-06-08 | Dimo Dietrich | Verfahren zur Abschätzung der Prognose und zur Prädiktion des Ansprechens auf eine Immuntherapie von Patienten mit malignen Erkrankungen |
| US10294518B2 (en) | 2016-09-16 | 2019-05-21 | Fluxion Biosciences, Inc. | Methods and systems for ultra-sensitive detection of genomic alterations |
| US20200010907A1 (en) | 2017-03-17 | 2020-01-09 | Mdxhealth Sa | Mgmt epigenetic deep-sequencing assay |
| US20180271710A1 (en) * | 2017-03-22 | 2018-09-27 | Bragi GmbH | Wireless earpiece for tinnitus therapy |
| WO2018237327A1 (en) * | 2017-06-22 | 2018-12-27 | Triact Therapeutics, Inc. | Methods of treating glioblastoma |
| US11628144B2 (en) | 2017-09-29 | 2023-04-18 | Triact Therapeutics, Inc. | Iniparib formulations and uses thereof |
| US11441182B2 (en) * | 2018-08-08 | 2022-09-13 | Virginia Commonwealth University | Multiplexed and recyclable single-molecule sensors for quantitative analysis of nucleic-acid biomarkers |
| CN109540856B (zh) * | 2018-11-08 | 2022-01-28 | 南京师范大学 | 一种基于荧光共振能量转移检测不同亚型乳腺癌细胞的试剂 |
| CN111551978B (zh) * | 2020-05-08 | 2022-09-27 | 中国辐射防护研究院 | 一种放射性土壤样品采样过程不确定度的评定方法 |
| WO2023108145A1 (en) * | 2021-12-10 | 2023-06-15 | Nuprobe Usa, Inc. | Universal probes for amplification and detection of nucleic acids |
| WO2024102722A1 (en) | 2022-11-07 | 2024-05-16 | Neoimmunetech, Inc. | Methods of treating a tumor with an unmethylated mgmt promoter |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4437975A (en) * | 1977-07-20 | 1984-03-20 | Mobil Oil Corporation | Manufacture of lube base stock oil |
| CA1340843C (en) | 1987-07-31 | 1999-12-07 | J. Lawrence Burg | Selective amplification of target polynucleotide sequences |
| KR0148265B1 (ko) | 1988-12-16 | 1998-10-15 | 에프.지이.엠 헤르만스 | 자가-지속 서열 복제 시스템 |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| EP0761231B1 (en) | 1992-06-25 | 2000-01-12 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine composition containing adjuvants |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| EP0772619B2 (en) | 1994-07-15 | 2010-12-08 | The University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US6117635A (en) | 1996-07-16 | 2000-09-12 | Intergen Company | Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6291430B1 (en) * | 1997-09-12 | 2001-09-18 | Ludwig Institute For Cancer Research | Mage-3 peptides presented by HLA class II molecules |
| DE69942214D1 (de) * | 1998-02-05 | 2010-05-12 | Glaxosmithkline Biolog Sa | Verfahren zur Reinigung oder Herstellung der MAGE Protein |
| US6768000B1 (en) * | 1998-06-12 | 2004-07-27 | Intergen Company | Multi-fluorescent hairpin energy transfer oligonucleotides |
| DK1104306T3 (da) | 1998-08-10 | 2006-05-22 | Antigenics Inc | Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf |
| US6667037B1 (en) * | 1998-10-09 | 2003-12-23 | Ludwig Institute For Cancer Research | Isolated peptides which bind to HLA-B35 molecules, larger peptides which contain these, nucleic acid molecules encoding peptides, and uses thereof |
| TR200103018T2 (tr) | 1999-04-19 | 2002-02-21 | Beecham Biologicals S.A. Smithkline | İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri. |
| US6331393B1 (en) * | 1999-05-14 | 2001-12-18 | University Of Southern California | Process for high-throughput DNA methylation analysis |
| US20040033490A1 (en) * | 2000-03-31 | 2004-02-19 | Laird Peter W. | Epigenetic sequences for esophageal adenocarcinoma |
| DE60217837T2 (de) | 2001-03-15 | 2007-10-25 | Jacques Schrenzel | Nachweis von methicillin-resistenten staphylococcus aureus bakterien (mrsa) |
| US20030134404A1 (en) | 2001-11-26 | 2003-07-17 | Lochrie Michael A. | Methods for producing stocks of recombinant AAV virions |
| EP1482795B1 (en) | 2002-02-04 | 2009-11-11 | Corixa Corporation | New immunoeffector compounds |
| DE10215770A1 (de) * | 2002-04-10 | 2003-10-30 | Michael Giesing | Verfahren zum Nachweis methylierter und/oder nichtmethylierter Cytosine in Nukleinsäuren, dessen Verwendung sowie entsprechende Analysekits |
| WO2004067726A2 (en) | 2003-01-29 | 2004-08-12 | Keck Graduate Institute | Isothermal reactions for the amplification of oligonucleotides |
| WO2004087957A2 (en) | 2003-04-03 | 2004-10-14 | Oncomethylome Sciences S.A. | Hypermethylated genes and cervical cancer |
| US7881873B2 (en) * | 2003-04-29 | 2011-02-01 | The Jackson Laboratory | Systems and methods for statistical genomic DNA based analysis and evaluation |
| DE10329240A1 (de) * | 2003-06-24 | 2005-01-20 | Epigenomics Ag | Verfahren zur Analyse des Cytosin-Methylierungsstatus von Cancer-Testis-Antigenen für eine individualisierte Immuntherapie |
| DE10338308B4 (de) * | 2003-08-15 | 2006-10-19 | Epigenomics Ag | Verfahren zum Nachweis von Cytosin-Methylierungen in DNA |
| WO2005042713A2 (en) | 2003-10-28 | 2005-05-12 | The Johns Hopkins University | Quantitative multiplex methylation-specific pcr |
| US20050130170A1 (en) * | 2003-12-16 | 2005-06-16 | Jeanne Harvey | Identification and verification of methylation marker sequences |
| WO2006040187A2 (en) * | 2004-10-11 | 2006-04-20 | Epigenomics Ag | A method for the carry-over protection in dna amplification systems targeting methylation analysis achieved by a modified pre-treatment of nucleic acids |
| US20070059753A1 (en) * | 2005-09-15 | 2007-03-15 | Tatiana Vener | Detecting gene methylation |
| GB0612342D0 (en) * | 2006-06-21 | 2006-08-02 | Glaxosmithkline Biolog Sa | Method |
| GB0700374D0 (en) | 2007-01-09 | 2007-02-14 | Oncomethylome Sciences S A | NDRG family methylation markers |
| US8911937B2 (en) * | 2007-07-19 | 2014-12-16 | Brainreader Aps | Method for detecting methylation status by using methylation-independent primers |
-
2008
- 2008-09-17 CN CN200880117371.0A patent/CN101932723B/zh not_active Expired - Fee Related
- 2008-09-17 JP JP2010524578A patent/JP5406839B2/ja not_active Expired - Fee Related
- 2008-09-17 WO PCT/GB2008/003145 patent/WO2009037441A1/en not_active Ceased
- 2008-09-17 KR KR1020107008201A patent/KR20100085917A/ko not_active Abandoned
- 2008-09-17 WO PCT/GB2008/003142 patent/WO2009037438A1/en not_active Ceased
- 2008-09-17 US US12/678,702 patent/US8481700B2/en not_active Expired - Fee Related
- 2008-09-17 EP EP08806301.1A patent/EP2201131B8/en active Active
- 2008-09-17 CA CA2699853A patent/CA2699853A1/en not_active Abandoned
- 2008-09-17 BR BRPI0817008A patent/BRPI0817008A2/pt not_active IP Right Cessation
- 2008-09-17 CA CA2699856A patent/CA2699856C/en active Active
- 2008-09-17 NZ NZ596545A patent/NZ596545A/xx not_active IP Right Cessation
- 2008-09-17 EP EP08806298A patent/EP2198045A1/en not_active Withdrawn
- 2008-09-17 US US12/678,706 patent/US9050280B2/en active Active
- 2008-09-17 EA EA201000334A patent/EA017879B1/ru not_active IP Right Cessation
- 2008-09-17 MX MX2010002965A patent/MX2010002965A/es not_active Application Discontinuation
- 2008-09-17 AU AU2008300397A patent/AU2008300397A1/en not_active Abandoned
- 2008-09-17 NZ NZ583796A patent/NZ583796A/en not_active IP Right Cessation
-
2010
- 2010-03-11 DO DO2010000076A patent/DOP2010000076A/es unknown
- 2010-03-16 IL IL204525A patent/IL204525A0/en unknown
- 2010-03-16 ZA ZA2010/01878A patent/ZA201001878B/en unknown
- 2010-03-19 CO CO10033047A patent/CO6260156A2/es not_active Application Discontinuation
- 2010-04-01 MA MA32736A patent/MA31753B1/fr unknown
- 2010-06-16 CR CR11504A patent/CR11504A/es not_active Application Discontinuation
-
2013
- 2013-06-13 US US13/917,108 patent/US20130302363A1/en not_active Abandoned
-
2015
- 2015-06-08 US US14/733,152 patent/US10053724B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA31753B1 (fr) | Detection amelioree de l'expression de mage-a | |
| Christiansen et al. | DNA methylation age is associated with mortality in a longitudinal Danish twin study | |
| Cervena et al. | Methylation-based therapies for colorectal cancer | |
| Montgomery et al. | High-resolution DNA melting analysis in clinical research and diagnostics | |
| US8239136B2 (en) | Method, computer system and computer-readable medium for determining a probability of colorectal cancer in a test subject | |
| CN106460068B (zh) | 胃癌的检测试剂盒或装置以及检测方法 | |
| JP6722659B2 (ja) | 結腸直腸癌のためのメチル化マーカー | |
| CN102209791B (zh) | Hla基因型的检测 | |
| JP2014524735A5 (enExample) | ||
| EP4574992A3 (en) | Combinatorial dna screening | |
| Soares Bispo Santos Silva et al. | Evaluation of DNA methylation markers and their potential to predict human aging | |
| RU2013158861A (ru) | Способы и композиции для предсказания активности модулятора ретиноидного х-рецептора | |
| KR20170026322A (ko) | 다제 내성균의 검출 방법 | |
| Papur et al. | Mutation analysis of ATP7B gene in Turkish Wilson disease patients: identification of five novel mutations | |
| ES2759507T3 (es) | Método para predecir una respuesta de tratamiento a un antagonista de V1B en un paciente con síntomas depresivos y/o de ansiedad | |
| Park et al. | Traveller-associated high-level ciprofloxacin-resistant Salmonella enterica Serovar Kentucky in the Republic of Korea | |
| JP2017511138A5 (enExample) | ||
| Tepper et al. | A biotinylated cpFIT-PNA platform for the facile detection of drug resistance to artemisinin in plasmodium falciparum | |
| Spence et al. | Intraclonal diversity in follicular lymphoma analyzed by quantitative ultradeep sequencing of noncoding regions | |
| WO2003026488A3 (en) | Diagnosis and treatment of vascular disease | |
| MX2007008984A (es) | Marcadores de cancer y metodos de deteccion. | |
| Kai et al. | Mutations in the drug resistance‐determining region of Mycobacterium lepromatosis isolated from leprosy patients in Mexico | |
| WO2021188186A2 (en) | Detection of gene polymorphisms | |
| Pejanovic-Skobic et al. | Lack of association of SCN2A rs17183814 polymorphism with the efficacy of lamotrigine monotherapy in patients with focal epilepsy from Herzegovina area, Bosnia and Herzegovina | |
| Gualtieri et al. | Frequency and characterisation of spontaneous lipiarmycin-resistant Enterococcus faecalis mutants selected in vitro. |